Skip to main content
Open Access Publications from the University of California

A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced Fc RIIIa-Mediated Antiviral Activity In Vitro but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques

  • Author(s): Moldt, B.
  • Shibata-Koyama, M.
  • Rakasz, E. G
  • Schultz, N.
  • Kanda, Y.
  • Dunlop, D. C
  • Finstad, S. L
  • Jin, C.
  • Landucci, G.
  • Alpert, M. D
  • Dugast, A.-S.
  • Parren, P. W. H. I
  • Nimmerjahn, F.
  • Evans, D. T
  • Alter, G.
  • Forthal, D. N
  • Schmitz, J. E
  • Iida, S.
  • Poignard, P.
  • Watkins, D. I
  • Hessell, A. J
  • Burton, D. R
  • et al.

Eliciting neutralizing antibodies is thought to be a key activity of a vaccine against human immunodeficiency virus (HIV). However, a number of studies have suggested that in addition to neutralization, interaction of IgG with Fc gamma receptors (FcγR) may play an important role in antibody-mediated protection. We have previously obtained evidence that the protective activity of the broadly neutralizing human IgG1 anti-HIV monoclonal antibody (MAb) b12 in macaques is diminished in the absence of FcγR binding capacity. To investigate antibody-dependent cellular cytotoxicity (ADCC) as a contributor to FcγR-associated protection, we developed a nonfucosylated variant of b12 (NFb12). We showed that, compared to fully fucosylated (referred to as wild-type in the text) b12, NFb12 had higher affinity for human and rhesus macaque FcγRIIIa and was more efficient in inhibiting viral replication and more effective in killing HIV-infected cells in an ADCC assay. Despite these more potent in vitro antiviral activities, NFb12 did not enhance protection in vivo against repeated low-dose vaginal challenge in the simian-human immunodeficiency virus (SHIV)/macaque model compared to wild-type b12. No difference in protection, viral load, or infection susceptibility was observed between animals given NFb12 and those given fully fucosylated b12, indicating that FcγR-mediated activities distinct from FcγRIIIa-mediated ADCC may be important in the observed protection against SHIV challenge.

Main Content
Current View